BioVector? HCCLM9 人高轉(zhuǎn)移肝癌細(xì)胞系 / BioVector? HCCLM9 Human High-Metastatic Hepatocellular Carcinoma Cell Line

通用定義 / General Definition:

BioVector? HCCLM9 是一種具有極高轉(zhuǎn)移潛能的人源肝細(xì)胞癌（HCC）細(xì)胞系。該細(xì)胞系是通過將人肝癌細(xì)胞在裸鼠體內(nèi)進(jìn)行多次原位接種和肺轉(zhuǎn)移篩選而建立的“LM”系列（Liver Metastasis）中的高端型號。與較低轉(zhuǎn)移能力的 HCCLM3 相比，HCCLM9 表現(xiàn)出更強(qiáng)的上皮-間充質(zhì)轉(zhuǎn)化（EMT）特征、更高的侵襲力以及極高的肺轉(zhuǎn)移率。它是研究肝癌轉(zhuǎn)移分子機(jī)制、腫瘤血管生成以及評價(jià)抗轉(zhuǎn)移藥物療效的理想模型。

BioVector? HCCLM9 is a human highly metastatic hepatocellular carcinoma (HCC) cell line. It was established as part of the "LM" (Liver Metastasis) series through successive rounds of orthotopic implantation and pulmonary metastasis screening in nude mice. Compared to the lower-metastatic HCCLM3, HCCLM9 exhibits enhanced epithelial-mesenchymal transition (EMT) features, greater invasiveness, and a significantly higher rate of spontaneous lung metastasis. It serves as a premier model for investigating the molecular mechanisms of HCC metastasis, tumor angiogenesis, and evaluating the efficacy of anti-metastatic therapeutic agents.

BioVector? HCCLM9 技術(shù)說明書 (Technical Datasheet)

中文版說明書 (Chinese Datasheet)

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? HCCLM9 人高轉(zhuǎn)移肝癌細(xì)胞

• 組織來源： 肝臟 (Liver)

• 生長特性： 貼壁生長

• 細(xì)胞形態(tài)： 上皮樣，呈多角形或紡錘形，生長密集時(shí)呈鋪路石狀。

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? DMEM 培養(yǎng)基（高糖）。

• 血清添加： 10% BioVector? 優(yōu)質(zhì)胎牛血清 (FBS)。

• 培養(yǎng)環(huán)境： 37 攝氏度，5% $CO_2$。

• 傳代比例： 1:3 至 1:6；該細(xì)胞生長迅速，建議在匯合度達(dá)到 80-90% 時(shí)及時(shí)傳代。

3. 細(xì)胞應(yīng)用

• 轉(zhuǎn)移機(jī)制研究： 研究循環(huán)腫瘤細(xì)胞（CTC）的形成及遠(yuǎn)處器官（如肺部）定殖的生物學(xué)過程。

• EMT 轉(zhuǎn)化分析： 探索 Snail, Twist, Vimentin 等標(biāo)志物在肝癌細(xì)胞獲得侵襲能力中的作用。

• 動物造模： 用于構(gòu)建裸鼠肝癌原位移植模型或肺轉(zhuǎn)移模型，觀察藥物對腫瘤生長和轉(zhuǎn)移的抑制。

4. 注意事項(xiàng)

• 遺傳穩(wěn)定性： 隨著傳代次數(shù)增加，細(xì)胞的高轉(zhuǎn)移特性可能出現(xiàn)減弱。BioVector? 建議實(shí)驗(yàn)使用復(fù)蘇后 10 代以內(nèi)的細(xì)胞。

• 細(xì)胞接種： 進(jìn)行體內(nèi)轉(zhuǎn)移實(shí)驗(yàn)時(shí)，需嚴(yán)格控制接種細(xì)胞的數(shù)量和活力，以確保肺轉(zhuǎn)移結(jié)節(jié)的可重復(fù)性。

English Datasheet

1. General Product Information

• Product Name: BioVector? HCCLM9 Human Highly Metastatic Hepatocellular Carcinoma Cell Line

• Tissue Source: Liver

• Growth Properties: Adherent

• Morphology: Epithelial-like; polygonal or spindle-shaped, forming a cobblestone pattern at high density.

2. Culture Conditions

• Basal Medium: BioVector? DMEM (High Glucose).

• Serum Supplement: 10% BioVector? Fetal Bovine Serum (FBS).

• Incubation: 37 degrees Celsius, 5% $CO_2$.

• Subculturing: 1:3 to 1:6 ratio; due to its rapid proliferation, subculture when cells reach 80-90% confluence.

3. Applications

• Metastasis Research: Studying the biological stages of the metastatic cascade, from intravasation to successful colonization in distant organs like the lungs.

• EMT Analysis: Investigating the signaling pathways and transcription factors (e.g., TGF-$\beta$, Snail) that drive the conversion from a sedentary to a migratory phenotype.

• In Vivo Modeling: Creating orthotopic or tail-vein injection models in nude mice to assess tumor burden and metastatic index.

4. Key Usage Notes

• Maintenance of Phenotype: The high metastatic potential of HCCLM9 can drift over long-term culture. BioVector? recommends using low-passage cells (within 10 passages post-thawing) for critical metastasis assays.

• Culture Quality: Ensure the use of high-glucose DMEM to support the aggressive metabolic demands of this highly malignant cell line.

注意 / Note: BioVector? HCCLM9 應(yīng)在生物安全二級 (BSL-2) 條件下操作。由于其極強(qiáng)的侵襲性和增殖能力，它是開發(fā)靶向肝癌轉(zhuǎn)移藥物（如 VEGF 或 MET 抑制劑）的關(guān)鍵工具。

BioVector? HCCLM9 should be handled under Biosafety Level 2 (BSL-2) conditions. Given its aggressive invasive and proliferative capacity, it is a pivotal tool for developing drugs targeting HCC metastasis, such as VEGF or MET inhibitors.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址

http://www.nedfriskphoto.com